Discovery Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Discovery Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-1,500,000	Closed	-$99.4M	–	127
2016 Q3	$99.4M	Buy	+1,500,000	New	+$92.8M	2.11%	16

Other funds holding XBI

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $49.6B AUM 39.59% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Discovery Capital Management's XBI Position: Q4 2016 in Review

Discovery Capital Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2016, closing a stake of 1,500,000 shares — an estimated $99.4M sold.

Discovery Capital Management first reported a position in XBI in Q3 2016 and held it in 1 quarter. The position peaked at $99.4M in Q3 2016. 274 funds tracked by Wall St. Rank hold XBI as of Q4 2016.

Discovery Capital Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2016 after selling out during the quarter.
Discovery Capital Management sold 1,500,000 State Street SPDR S&P Biotech ETF shares in Q4 2016, an estimated $99.4M.
Discovery Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q3 2016 and held it in 1 quarter.
Discovery Capital Management's State Street SPDR S&P Biotech ETF position peaked at $99.4M in Q3 2016.
274 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2016.

Based on Discovery Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.